@article{17978,
  keywords = {Adolescent, Adult, Animals, Antigens, Bacterial, Child, Female, Foot, Fusidic Acid, Glycolipids, Humans, Leprosy, lepromatous, Male, Mice, Microbial Sensitivity Tests, Mycobacterium leprae, polymerase chain reaction, Skin, Spirometry, Time Factors},
  author = {Franzblau S G and Chan G P and Garcia-Ignacio B G and Chavez V E and Livelo J B and Jimenez C L and Parrilla M L and Calvo R F and Williams D L and Gillis T P},
  title = {Clinical trial of fusidic acid for lepromatous leprosy.},
  abstract = {<p>Fusidic acid was assessed for antileprosy activity in nine lepromatous leprosy patients. Patients received fusidic acid at either 500 mg/day for 12 weeks or 750 mg/day for 4 weeks followed by 500 mg/day for 8 weeks. All patients showed time-dependent clinical improvement and decreases in bacillary morphological index, radiorespirometric activity and PCR signal, and in serum phenolic glycolipid I. Fusidic acid appears to be a weakly bactericidal antileprosy agent which may have a role in the multidrug treatment of leprosy pending an evaluation of lepra-reaction-suppressive activity.</p>},
  year = {1994},
  journal = {Antimicrobial agents and chemotherapy},
  volume = {38},
  pages = {1651-4},
  month = {1994 Jul},
  issn = {0066-4804},
  doi = {10.1128/aac.38.7.1651},
  language = {eng},
}